10-K/A: Pharma-Bio Serv Files Amendment to 10-K, Addressing Governance and Executive Compensation

Pharma-Bio Serv, Inc. files an amendment to its annual report on Form 10-K to include information required by Items 10 through 14 of Part III, focusing on directors, executive compensation, security ownership, related transactions, and principal accountant fees.

Summary

• Pharma-Bio Serv, Inc. has filed an amendment (Form 10-K/A) to its annual report for the fiscal year ended October 31, 2024.
• The amendment primarily addresses Items 10 through 14 of Part III of the original Form 10-K, which pertain to directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, and accountant fees.
• The original 2024 Form 10-K was filed on January 29, 2025, and this amendment speaks as of that date, with changes only to the cover page and specified items.
• The company's common stock outstanding as of January 24, 2025, was 22,958,143 shares.
• The aggregate market value of common stock held by non-affiliates as of April 30, 2024, was $13,638,206.
• The Board of Directors is divided into three classes with staggered three-year terms.
• The company has an Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, all composed of independent directors.
• The company has adopted a Code of Ethics applicable to all employees, officers, and directors, including an insider trading policy.
• Executive compensation details are provided for the principal executive officer (Victor Sanchez) and other executive officers (Pedro Lasanta).
• Director compensation includes a quarterly retainer fee of $12,500 and an annual stock option grant of 20,000 shares.
• The company leases office facilities from an affiliate of a past Chairman of the Board with monthly rental payments of $14,561.
• The company entered into an agreement with an AI company in which a board member holds a minority interest, obtaining a Lead Generation Technology Platform, a membership interest, and an option for an additional interest for $250,000.
• Crowe PR PSC billed the company $117,590 in 2024 for audit fees, audit-related fees, and other services.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with no strong positive or negative sentiment. The presence of related party transactions and the AI agreement introduces a slightly cautious tone.

Positives

• The company has established Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors, ensuring oversight and accountability.
• The company has a Code of Ethics and Insider Trading Policy in place to promote compliance with laws and regulations.
• The company is investing in innovative technologies like AI to improve business development and recruitment processes.

Negatives

• The company engages in related party transactions, such as leasing office space from an affiliate of a past Chairman, which could raise concerns about potential conflicts of interest.
• A board member has an indirect minority interest in a company that Pharma-Bio Serv has contracted with, which could raise concerns about potential conflicts of interest.

Risks

• Related party transactions, such as the office lease and the AI agreement, could present potential conflicts of interest and require careful monitoring.
• Failure to maintain effective internal controls over financial reporting could adversely affect the company's ability to accurately report financial information.
• The company's reliance on key personnel, such as the CEO and CFO, could pose a risk if they were to leave the company.

Future Outlook

The document does not contain specific forward-looking statements or guidance.

Industry Context

The document provides insight into the corporate governance practices, executive compensation, and related party transactions of a small public company in the pharmaceutical services industry. These disclosures are standard for SEC filings and allow investors to assess the company's management and potential conflicts of interest.

Comparison to Industry Standards

• The director compensation structure, including a quarterly retainer and stock options, is fairly standard for small public companies.
• Related party transactions, while not uncommon, are generally scrutinized by investors and regulators to ensure they are conducted at arm's length and are beneficial to the company.
• The audit fees paid to Crowe PR PSC appear reasonable for a company of this size and complexity.

Related Party Transactions

• The Company conducts its headquarters administrative operations in office facilities located in Dorado, Puerto Rico (the Office Facilities).
• The Office Facilities are leased from an affiliate of our past Chairman of the Board and greater than 5% stockholder.
• On August 19, 2024, the Company entered into an agreement (the 'AI Agreement') with a company which Dov Perlysky, a member of our Board of Directors, and Mr. Perlysky's brother-in-law, Alan Stahler, indirectly hold a minority interest and are indirect managers of (the AI Company).

Stakeholder Impact

• Shareholders: The disclosures provide transparency regarding executive compensation, director independence, and potential conflicts of interest.
• Employees: The Code of Ethics and Insider Trading Policy set expectations for ethical conduct and compliance with regulations.
• Customers and Suppliers: The document does not directly address the impact on customers or suppliers.

Key Dates